drugset

drugset / Trial / NCT00390975

Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis

NCT00390975 ↗

Phase 4 Terminated 40 enrolled Novartis

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis treated with tegaserod over 2 weeks.

Timeline

Start: 2007-01
Primary completion: 2007-03
Completion: 2007-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tegaserod	Small molecule	—	—

Indications